echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > These regulations were implemented on July 1st, affecting all pharmaceutical sane people.

    These regulations were implemented on July 1st, affecting all pharmaceutical sane people.

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    . Pharmaceutical Network July 2nd, with the implementation of the Drug Administration Law in December 2019, a number of supporting regulations and policies in 2020 have come into effect, and the regulations implemented on July 1, 2020 include the Measures for the Supervision and Administration of Drug Production, the Measures for the Administration of Drug Registration, the Appendix to Biological Products, the Code of Quality Management of Drug Clinical Trials, the Registration of Biological Products Classification and declaration data requirements, chemical registration classification and declaration data requirements, non-organized emission control standards for volatile organic compounds, technical requirements for ozone generators for water treatment, code of conduct for live webcast marketing, medical device cleaning agents, independent software for medical device manufacturing quality management specifications, and adjustment of the provisional tax rate for imports of medical devices in 2020..
    the measures for drug supervision and management and drug registration management measures .
    . On March 30, 2020, the official website of the State Administration of Market Supervision and Administration published the Measures for the Supervision and Administration of Drug Production, which will be put into effect on July 1, 2020. As the core supporting regulations in the field of drug supervision, the two measures fully implement the latest requirements of the Vaccine Administration Law and the Drug Administration Law, fully reflect the results of the reform of the national drug review and approval system in recent years, make a new system design for drug registration management and drug production supervision, make a new system design, more clear problem orientation, more scientific supervision and management, and comprehensively improve the rule of law, standardization level of drug registration and drug production, and ensure the effective and effective quality of drug production..
    two methods to encourage drug research and development innovation, the system solves the actual problems encountered in the process of declaration of innovative drugs, and fills some of the gaps in the previous system. The simultaneous revision and publication of the two measures reflect the coordination between drug registration and post-marketing supervision..
    the two measures further clarify the national and provincial drug regulatory departments in the drug registration management and day-to-day supervision of the division of power and supervision and inspection requirements, to ensure that drug registration acceptance, review, inspection and inspection and other links effectively linked, formed a drug research and development, registration declaration, on-site verification, after-market supervision of the whole process of supervision chain, to solve the drug registration and regulatory licensing matters over the years in mutual dependence, lack of procedures. The newly revised Measures for the Supervision and Administration of Drug Production clearly state that on-site verification of drug registration and compliance with the quality management norms of pharmaceutical production before listing can be carried out simultaneously, and a number of licensing problems can be resolved through one inspection..
    two methods also further clarify the
    enterprise
    the main responsibility. The two methods follow the scientific supervision concept, optimize the review and approval process, fully reflect the "management" reform requirements..
    two methods to encourage drug research and development innovation, the system solves the actual problems encountered in the process of declaration of innovative drugs, and fills some of the gaps in the previous system. The simultaneous revision and publication of the two measures reflect the coordination between drug registration and post-marketing supervision..
    the two measures further clarify the national and provincial drug regulatory departments in the drug registration management and day-to-day supervision of the division of power and supervision and inspection requirements, to ensure that drug registration acceptance, review, inspection and inspection and other links effectively linked, formed a drug research and development, registration declaration, on-site verification, after-market supervision of the whole process of supervision chain, to solve the drug registration and regulatory licensing matters over the years in mutual dependence, lack of procedures. The newly revised Measures for the Supervision and Administration of Drug Production clearly state that on-site verification of drug registration and compliance with the quality management norms of pharmaceutical production before listing can be carried out simultaneously, and a number of licensing problems can be resolved through one inspection..
    two approaches also further clarify the corporate responsibility. The two methods follow the scientific supervision concept, optimize the review and approval process, fully reflect the "management" reform requirements..
    theof the announcement of the implementation of the measures for production supervision and management.
    . On the day of the official publication of the Measures, the Drug Administration issued the Notice on the Implementation of the New Amendment <> Related Matters, making it clear that the application for a pharmaceutical production license for an enterprise and the commissioned production of drugs shall be connected with the old "Measures" in accordance with the following means:
    from July 1, 2020, the applicant signed for a pharmaceutical production license shall be processed in accordance with the relevant provisions of the Measures. The existing Drug Production License will remain in effect for the duration of the period..
    who has obtained the Drug Production License for the drug market license holder (hereinafter referred to as "the "holder") entrusts the production of the preparation, in accordance with the provisions of Article 16 of the Measures on Production concerning the change of the production address or the scope of production. If the original
    drug
    entrusted to the production of the batch, it shall continue to be valid for the period of validity..Where the holder of the
    entrusts the production of preparations, a entrustment agreement and a quality agreement shall be signed with an eligible pharmaceutical production enterprise, and the contents of the entrustment agreement and quality agreement shall comply with the relevant laws
    regulations
    regulations..If the holder of the
    is approved for listing in the form of entrusted production during the pilot period until the implementation of the newly revised Measures for the Administration of Drug Registration, the holder shall apply to the local provincial drug regulatory department for a drug production license by July 1, 2020..
    , having obtained a Drug Production License in accordance with the law before July 1, 2020, and its workshop or production line has not carried out gmp compliance checks, gmp compliance checks shall be carried out in accordance with the provisions of the Production Measures..
    theof upgrading and upgrading the drug registration-related system.
    . On June 17, the official website of the State Drug Administration issued the "State Drug Administration on the upgrading of the drug registration-related system (No. 72 of 2020)"; .
    the of the Appendix to Biologics. 
    . On April 26, the new version of the GMP Appendix Biologics, which is a supporting document of the Code of Quality Management of Pharmaceutical Production (revised in 2010), will come into effect on July 1, 2020. Among them, article 59 of the appendix, enterprises using real-time data acquisition information system to record data, because the information construction needs a certain period of time, should meet the relevant requirements by July 1, 2022. .
    the new edition of "Biological Products" a total of eight chapters and 63 articles, compared with the implementation of the old version of the "biological products" appendix, compared with The implementation of March 1, 2011, added 6 articles, revised 15 articles, the amendment of the provisions mainly around the further strengthening of vaccine management, regulate vaccine production and quality management behavior. .
    of the Code of Quality Management for Drug Clinical Trials. 
    . On April 26, the State Drug Administration and the State Health and Care Commission jointly released a new version of the "Quality Management Code for Drug Clinical Trials", the new version of China's GCP will be officially implemented on July 1, 2020, which is an important step in China's drug registration into the era of globalization, but also the pharmaceutical industry chain to put forward higher normative requirements. .
    the overall framework and chapter content of the new version of the Code of Quality Management of Drug Clinical Trials have been adjusted and supplemented more substantially than the current GCP, and the overall framework structure has increased the number of words from more than 9,000 words to more than 29,000 words, and the chapters have been adjusted from the original 13 chapters, 70 articles to 8 chapters and 84. Add up to the terms clause, from the original 19 to 40, while the term and its definition are advanced to chapter two, to facilitate the reader to read and understand the content of the specification. .
    for the release of the new version of the Code, the industry generally believes that the country is the next China's drug clinical research quality to improve the new requirements. This means that pharmaceutical companies in the future in the development of drugs, to further strengthen the quality management of clinical trials. At the same time, for the production, sales links to do the quality of strict control. .
    guidelines for the preservation of essential documents for drug clinical trials. 
    . On June 8, the State Drug Administration issued a circular on the issuance of guidelines for the preservation of essential documents for drug clinical trials (No. 37 of 2020), which will come into effect on July 1, 2020. .
    Pharmaceutical Clinical Trial Seeking Documents are documents that evaluate the implementation and data quality of drug clinical trials, and are used to demonstrate that researchers, applicants and inspectors have complied with the Code of Quality Management of Drug Clinical Trials and the relevant legal and regulatory requirements for drug clinical trials during clinical trials. As the basis for confirming the authenticity of clinical trial implementation and the integrity of the data collected, the necessary documents for drug clinical trials are the important contents of the applicant's inspection and drug supervision and administration departments examining clinical trials, and should meet the requirements of the necessary document management in the Code of Quality Management of Drug Clinical Trials. This Guideline applies to the preservation of the necessary documents for drug clinical trials for the purpose of applying for drug registration. .
    requirements for the registration classification and declaration of biological products. 
    . On June 30, the State Drug Administration issued a circular on the "Registration classification and declaration of biological products" (No. 43 of 2020). With regard to the classification of biological products, it will be implemented from 1 July 2020. The requirements for the declaration of biological products will be in effect from 1 October 2020. By September 30, 2020, the filing of the information may be submitted as required. .
    requirements for the classification and declaration of chemical registration. 
    . On June 30, the State Drug Administration issued a circular on the "Regulation and Declaration of Chemical Drugs Registration" (No. 44 of 2020). With regard to the classification of chemical registrations, it will be implemented from 1 July 2020. The requirements for the registration and declaration of chemicals will be implemented from 1 October 2020. By September 30, 2020, the filing of the information may be submitted as required. .
    non-organizing emission control standards for volatile organic samuls . 
    . In May 2019, the Ministry of Ecological Environment, together with the State Administration of Market Supervision and Administration, issued the Non-Organizational Emission Control Standards for Volatile Organics (GB37822-2019), requiring new enterprises to implement the standards from July 1, 2019, and existing enterprises to implement these standards from July 1, 2020. From July 1, 2020, all enterprises fully implement the national standard GB37822! Nine types of VOCs violations, will be the focus of local law enforcement. VOCs mainly include 30 industries, such as pharmaceuticals. .
    standards define voCs material storage non-tissue emission control requirements, VOCs material transfer and transmission of non-tissue emission control requirements, process VOCs unorganized emission control requirements, equipment and pipeline components VOCs leak control requirements, open liquid surface VOCs unorganized emission control requirements, as well as VOCs non-tissue emission collection and treatment system requirements, enterprise plant and surrounding pollution monitoring requirements. .
    the technical requirements of ozone generators for water treatment . 
    . In September 2019, the National Standards Committee issued THE GB/T37894-2019 Technical Requirements for Ozone Generators for Water Treatment, which provides for the classification, model marking and specifications, structural design and materials, general regulations, requirements, test methods, inspection rules, markings, packaging, transportation and storage, and will be implemented on July 1, 2020! .
    the of the Live Webcast Marketing Code of Conduct. 
    . On June 24, the China Advertising Association issued the Code of Conduct for Webcast Marketing. This is the first domestic issue of the network broadcast marketing campaign on the special norms, innovative, will play a leading role in the healthy development of the industry. This Code will come into effect on July 1, 2020. .
    the Code requires that live webcast marketing activities should be fully, truthfully and accurately disclosed the information of goods or services, and consumers' right to know and to choose should be protected in accordance with the law; .
    the Code, the goods or services promoted by merchants shall comply with the requirements of relevant laws and regulations for the quality and safety of the use of goods, in line with the performance of use, the claim to adopt standards, promises, etc., there is no unreasonable risk of endangering the safety of persons or property. .
    merchants sell medicines,
    medical devices
    ,
    health food.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.